CoreWeave is a buy after Microsoft’s strong earnings report, Citi says

Citi upgraded CoreWeave to Buy from Neutral, setting a $160 price target that implies 55% upside, despite the stock's recent 37% decline. Analyst Tyler Radke cited robust AI demand, evidenced by Microsoft's strong Azure performance and increased capex, as a key driver for CoreWeave, noting Microsoft represents 72% of its 1Q25 revenue. Despite investor skepticism over CoreWeave's $9 billion Core Scientific acquisition and Radke's own concerns about customer concentration, the upgrade, which contrasts with the broader analyst consensus of 'Hold' ratings, propelled CoreWeave shares up 13% premarket.

Analysis

A contrarian upgrade from Citi has positioned CoreWeave (CRWV) as a potential 'buy the dip' opportunity, following a 37% stock decline over the past month. The analyst, Tyler Radke, raised the stock to Buy from Neutral with a $160 price target, implying 55% upside, citing robust and durable AI demand as a primary catalyst. This conviction is largely drawn from strong quarterly performance and increased capex guidance from Microsoft, a pivotal customer that constitutes 72% of CoreWeave's Q1 2025 revenue. Despite investor skepticism surrounding the recent $9 billion acquisition of Core Scientific, the market reacted positively to the upgrade with a 13% premarket surge. However, significant risks remain, including the noted customer concentration and concerns about CoreWeave's ability to expand its offerings. It is crucial to note that this bullish stance is a minority view on Wall Street, where 17 of 24 analysts currently rate the stock a Hold.

Key Decisions for Investors

• Investors with a higher risk appetite may consider the Citi upgrade a signal to initiate or add to positions, capitalizing on the recent 37% pullback and the strong AI demand outlook.
• Closely monitor CoreWeave's high dependency on Microsoft, as any change in MSFT's AI spending or strategy presents a significant concentration risk given it accounts for 72% of Q1 revenue.
• Track future management commentary regarding the integration of the Core Scientific acquisition and the company's strategy to 'move up the stack' to address key market concerns.
• Given the current analyst consensus is a 'Hold', investors should watch for any further ratings changes, as a broader shift in sentiment could serve as a powerful secondary catalyst for the stock.